Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00035048
NCT00035048
Completed
Phase 3

A Double-Blind, Placebo-Controlled, Multicenter Study of the Long-Term Efficacy of MK0869 in the Maintenance of Antidepressant Effect in Geriatric Outpatients With Major Depressive Disorder

Merck Sharp & Dohme LLC0 sites540 target enrollmentNovember 21, 2001
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsMajor Depressive Disorder
DrugsaprepitantComparator: placebo (unspecified)

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Major Depressive Disorder
Sponsor
Merck Sharp & Dohme LLC
Enrollment
540
Primary Endpoint
HAMD-17 score </= 10 after 10 weeks; maintenance of antidepressant effect for 6-10 months; tolerability
Status
Completed
Last Updated
8 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression.

Detailed Description

The duration of treatment is 10 weeks.

Registry
clinicaltrials.gov
Start Date
November 21, 2001
End Date
December 31, 2003
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

HAMD-17 score </= 10 after 10 weeks; maintenance of antidepressant effect for 6-10 months; tolerability

Time Frame: After 10 weeks & 6-10 months

Secondary Outcomes

  • CGI-S score change from Week 10 at Month 6; HAMD-17 total score change from Week 10 at Month 6; MADRS total score change at Month 6, HAMA total score change at Month 6(6 Months)

Similar Trials

Completed
Phase 3
Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED)Major Depressive Disorder
NCT00048594Merck Sharp & Dohme LLC800
Completed
Phase 3
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED)Major Depressive Disorder
NCT00035282Merck Sharp & Dohme LLC450
Completed
Phase 3
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED)Major Depressive Disorder
NCT00034983Merck Sharp & Dohme LLC900
Completed
Phase 2
A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe PsoriasisModerate to Severe Chronic Plaque Psoriasis
NCT00601107Genzyme, a Sanofi Company111
Completed
Phase 3
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)Major Depressive Disorder
NCT00035295Merck Sharp & Dohme LLC584